Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Below 50-Day Moving Average – What’s Next?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$17.21 and traded as low as C$16.38. Cipher Pharmaceuticals shares last traded at C$16.41, with a volume of 11,515 shares changing hands.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$17.00 price target on shares of Cipher Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of C$17.00.

Cipher Pharmaceuticals Trading Down 1.9%

The stock has a 50 day moving average of C$17.21 and a 200-day moving average of C$16.16. The company has a market capitalization of C$416.67 million, a P/E ratio of 13.79 and a beta of 1.10. The company has a current ratio of 1.25, a quick ratio of 2.67 and a debt-to-equity ratio of 0.32.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings results on Thursday, May 7th. The company reported C$0.33 earnings per share for the quarter. The business had revenue of C$17.39 million for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. On average, research analysts predict that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.